ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

被引：0

作者：

Kiladjian, Jean-Jacques ^{[1
]}

Marin, Francisca Ferrer ^{[2
]}

Al-Ali, Haifa Kathrin ^{[3
]}

Alvarez-Larran, Alberto ^{[4
]}

Beggiato, Eloise ^{[5
]}

Bieniaszewska, Maria ^{[6
]}

Breccia, Massimo ^{[7
]}

Buxhofer-Ausch, Veronika ^{[8
]}

Cerna, Olga ^{[9
,10
]}

Crisan, Ana Manuela ^{[11
]}

Danaila, Catalin ^{[12
]}

De Stefano, Valerio ^{[13
]}

Dohner, Konstanze ^{[14
]}

Empson, Victoria ^{[15
]}

Tybor, Joanna Gora ^{[16
]}

Griesshammer, Martin ^{[17
]}

Grosicki, Sebastian ^{[18
]}

Guglielmelli, Paola ^{[19
]}

Gutierrez Sr, Valentin Garcia ^{[20
]}

Heidel, Florian ^{[21
]}

Illes, Arpad ^{[22
]}

James, Chloe ^{[23
]}

Koschmieder, Steffen ^{[24
]}

Maria-Theresa, Krauth ^{[25
]}

Krejcy, Kurt ^{[15
]}

Lazaroiu, Mihaela Cornelia ^{[26
]}

Mayer, Jiri ^{[27
]}

Nagy, Zsolt ^{[28
]}

Palandri, Francesca ^{[29
]}

Pappa, Vasiliki ^{[30
]}

Reiter, Andreas ^{[31
]}

Sacha, Tomasz ^{[32
]}

Schlager, Stefanie ^{[15
]}

Schmidt, Stefan Ulrich ^{[33
]}

Terpos, Evangelos ^{[34
]}

Tomuleasa, Ciprian ^{[35
]}

Torregrosa, Jose Miguel ^{[36
]}

Unger, Martin ^{[15
]}

Woelfler, Albert ^{[37
]}

Xicoy, Blanca ^{[38
]}

Klade, Christoph ^{[15
]}

机构：

[1] Hop St Louis, Ctr Invest Clin, Paris, France

[2] HU Morales Meseguer, Serv Anat Patol, Murcia, Spain

[3] Univ Med Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[4] Hosp Clin Barcelona, ICMHO, Hematol Dept, Barcelona, Spain

[5] AOU Citta Salute & Sci, SC Clin Pharmacol, Turin, Italy

[6] INFN Torino, Turin, Italy

[7] Univ Clin Ctr, Gdansk, Poland

[8] Sapienza Univ Rome, Rome, Italy

[9] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Hematol, Prague, Czech Republic

[10] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic

[11] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[12] Reg Inst Oncol, Dept Clin Hematol, Iasi, Romania

[13] Catholic Univ, Dept Urol, Fdn Policlin Univ A Gemelli IRCCS, Med Sch, Rome, Italy

[14] Univ Hosp Ulm, Dept Radiol, Ulm, Germany

[15] AOP Hlth, Vienna, Austria

[16] Med Univ Lodz, Copernicus Mem Hosp Lodz, Dept Biostat & Translat Med, Dept Hematooncol, Lodz, Poland

[17] Univ Bochum, Univ Clin Hematol Oncol Hemostaseol & Palliat Care, Johannes Wesling Med Ctr Minden, Bochum, Germany

[18] Med Univ Silesia, Fac Hlth Sci Bytom, Dept Hematol & Canc Prevent, Katowice, Poland

[19] Univ Studi Firenze, Florence, Italy

[20] Univ Alcala, Hosp Univ Ramon & Cajal, Dept Urol, Inst Ramon & Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[21] Hannover Med Sch, Dept Hematol, Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany

[22] Univ Debrecen, Clin Ctr, Debrecen, Hungary

[23] Univ Bordeaux, Biol Cardiovasc Dis, Inserm, UMR1034, Pessac, France

[24] Aachen Bonn Cologne Dusseldorf CIO ABCD, Ctr Integrated Oncol, Aachen, Germany

[25] Med Univ Vienna, Clin Div Hematol & Hemostaseol, Dept Internal Medicine1, Vienna, Austria

[26] Policlin Diagnost Rapid, Brasov, Romania

[27] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[28] Semmelwe Egyet, Sportorvostan Tanszek, Budapest, Hungary

[29] Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[30] Univ Gen Hosp Attikon, Dept Internal Med & Res Unit 2, Athens, Greece

[31] Univ Med Ctr Mannheim, Dept Hematol & Oncol, Mannheim, Germany

[32] Jagiellonian Univ Hosp Krakow, Krakow, Poland

[33] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[34] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[35] Iuliu Hatieganu Univ Med & Pharm, MedFuture Res Ctr Advance Med, Cluj Napoca, Romania

[36] Univ Poitiers, Chu Poitiers, Poitiers, France

[37] Med Univ Graz, Oncol, Graz, Austria

[38] Univ Autonoma Barcelona, Inst Catala Oncol Badalona, Josep Carreras Leukemia Res Inst, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6635 / 6637

页数：3

共 50 条

[1] ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Kiladjian, Jean-Jacques
Marin, Francisca Ferrer
Al-Ali, Haifa Kathrin
Alvarez-Larran, Alberto
Beggiato, Eloise
Bieniaszewska, Maria
Breccia, Massimo
Buxhofer-Ausch, Veronika
Cerna, Olga
Crisan, Ana-Manuela
Danaila, Catalin Doru
De Stefano, Valerio
Doehner, Konstanze
Empson, Victoria
Gora-Tybor, Joanna
Griesshammer, Martin
Grosicki, Sebastian
Guglielmelli, Paola
Garcia-Gutierrez, Valentin
Heidel, Florian H.
Illes, Arpad
Tomuleasa, Ciprian
James, Chloe
Koschmieder, Steffen
Krauth, Maria-Theresa
Krejcy, Kurt
Lazaroiu, Mihaela-Cornelia
Mayer, Jiri
Nagy, Zsolt Gyoergy
Nicolini, Franck-Emmanuel
Palandri, Francesca
Pappa, Vassiliki
Reiter, Andreas Johannes
Sacha, Tomasz
Schlager, Stefanie
Schmidt, Stefan
Terpos, Evangelos
Unger, Martin
Woelfler, Albert
Cirici, Blanca Xicoy
Klade, Christoph
ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2299 - 2310
[2] SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
Verstovsek, Srdan
Komatsu, Norio
Gill, Harinder
Jin, Jie
Lee, Sung-Eun
Hou, Hsin-An
Sato, Toshiaki
Qin, Albert
Urbanski, Raymond
Shih, Weichung
Zagrijtschuk, Oleh
Zimmerman, Craig
Mesa, Ruben A.
FUTURE ONCOLOGY, 2022, 18 (27) : 2999 - 3009
[3] A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
Liu, Wang-Da
Feng, Po-Hao
Cheng, Chien-Yu
Chou, Chun-Liang
Lee, Chih-Hsin
Lu, Min-Chi
Liu, Po-Yu
Lee, Mei-Hui
Liao, Chun-Hsing
Chen, Mei-Chuan
Chen, Cheng-Pin
Hsu, Shang-Fu
Tzeng, Yu-Tien
Lin, Yi-Chun
Ou, Tsong-Yih
Qin, Albert
Tsai, Chan-Yen
Shih, Weichung Joe
Lee, Kang-Yun
Sheng, Wang-Huei
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (07) : 1575 - 1588
[4] Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
Masarova, Lucia
Komatsu, Norio
Gill, Harinder
Jin, Jie
Lee, Sung-Eun
Hou, Hsin-An
Sato, Toshiaki
Qin, Albert
Urbanski, Raymond
Shih, Weichung
Zagrijtschuk, Oleh
Zimmerman, Craig
Mesa, Ruben
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S405 - S405
[5] Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera
Qin, Albert
Wu, Daoxiang
Li, Yaning
Zhang, Jingjing
Wang, Wei
Shen, Weihong
Liao, Jason
Lin, Sheena
Chang, Cynthia
Chen, Haoqi
Cui, Jie
Su, Xia
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (06) : 1493 - 1502
[6] Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera
Kirito, Keita
Sugimoto, Yuka
Gotoh, Akihiko
Takenaka, Katsuto
Ichii, Michiko
Inano, Tadaaki
Shirane, Shuichi
Ito, Masafumi
Zagrijtschuk, Oleh
Qin, Albert
Kawase, Hiroaki
Sato, Toshiaki
Komatsu, Norio
Shimoda, Kazuya
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (06) : 675 - 683
[7] Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b
Qin, Albert
Wu, Daoxiang
Liao, Jason
Xie, Shuping
Chen, Haoqi
Gao, Yucheng
Cui, Jie
Su, Xia
Miyachi, Narihisa
Sato, Toshiaki
Li, Yaning
Zhang, Jingjing
Shen, Weihong
Wang, Wei
FRONTIERS IN PHARMACOLOGY, 2024, 15
[8] Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
Mesa, Ruben
Komatsu, Norio
Gill, Harinder
Jin, Jie
Lee, Sung-Eun
Hou, Hsin-An
Sato, Toshiaki
Qin, Albert
Urbanski, Raymond
Shih, Weichung
Zagrijtschuk, Oleh
Zimmerman, Craig
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S342 - S342
[9] Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
Lin, Hsien-Hong
Hsu, Shih-Jer
Lu, Sheng-Nan
Chuang, Wan-Long
Hsu, Chao-Wei
Chien, Rong-Nan
Yang, Sien-Sing
Su, Wei-Wen
Wu, Jaw-Ching
Lee, Tzong-Hsi
Peng, Cheng-Yuan
Tseng, Kuan-Chiao
Qin, Albert
Huang, Yi-Wen
Chen, Pei-Jer
JGH OPEN, 2021, 5 (08): : 929 - 940
[10] Ropeginterferon Alfa-2b for Young High-Risk Patients With Essential Thrombocythemia - Evaluation of Clinicohematologic Response and Safety Profile: Single-Center Experience
Popova-Labachevska, Marija
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S390 - S391

← 1 2 3 4 5 →